C-met and TMX2 antibodies
AssigneeR.G.C.C. Holdings AG
InventorIoannis Papasotiriou
Life of this patent
Estimating the term…
Abstract
The present invention provides: a novel method for the production of truly fully human monoclonal antibodies against specific antigens of our choice using isolated human blood cells. These antigens may include but are not limited to peptide sequences found in c-met and TMX2 proteins; an antibody specific for c-met protein produced with said method; an antibody specific for TMX2 protein produced with said method; and a new means and method for the diagnosis, prevention and/or cancer treatment by means of the aforementioned antibodies.
Claims2
A process for the production of monoclonal human antibodies by human cells, against a predefined antigen, said process comprising the steps of:
- a) isolating peripheral blood mononuclear cells from blood;
- b) generating mononuclear cells from the isolated peripheral blood mononuclear cells;
- c) generating immature dendritic cells from the generated mononuclear cells;
- d) isolating CD4+ and CD19+ cells from blood;
- e) pulsing at least the generated immature dendritic cells with the predefined antigen, without CD4+/CD19+ cells present;
- f) co-culturing the immature dendritic cells, the CD4+ cells and CD19+ cells in a culturing medium comprising a combination of GM-CSF, IL-4, TNF-α, sCD40L, IL-6, IL-21, IL-10 and anti-human IgM;
- g) pulsing at least the co-cultured immature dendritic cells, the CD4+ cells and CD19+ cells with at least the predefined antigen;
- h) generating mature dendritic cells from the immature dendritic cells by further co-culturing the immature dendritic cells, the CD4+ cells and CD19+ cells;
- i) inducing plasma cell formation;
- and
- j) inducing or not inducing Ig class switching towards IgG expression in the formed plasma cells.
Dependencies are inferred from the claim text.